Recent Developments in Targeted Therapies of the RAF-MEK and PI3K-AKT Pathways in Cancer Treatment

被引：0

作者：

Cremers, Lobke G. M. ^{[1
]}

Boonstra, Johannes ^{[1
]}

机构：

[1] Univ Utrecht, Cell Biol, Utrecht, Netherlands

来源：

CURRENT CANCER THERAPY REVIEWS | 2012年 / 8卷 / 03期

关键词：

AKT; Antitumor activity; Inhibitors; MEK; PI3K; RAF; Targeted drugs;

D O I：

10.2174/157339412802653209

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The RAF-MEK and PI3K-AKT pathways are both frequently deregulated in cancer, and often play a critical role in oncogenesis. In the previous years, major progress has been made in the development of targeted drugs against signaling kinases which are involved in carcinogenesis. Currently, targeted drugs against RAF, MEK, PI3K and AKT (among several others) have entered clinical investigation. Here we describe tumor causing mutations of these kinases, as well as the small molecule inhibitors that target these kinases, which contributes to improved ways of treating human cancer.

引用

页码：205 / 217

页数：13

共 50 条

[21] Effect of everolimus and gefitinib on PI3K/akt/mTOR and raf/MEK/ERK pathways in NSCLC cells.
Dong, S.
Zhang, X.
Chang, H.
Guo, A.
Zhu, J.
Yang, S.
Wu, Y.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[22] Targeting the PI3K-AKT-mTOR and RAF-MEK-ERK pathways in HER2 amplified breast cancer models
De, Pradip
Sun, Yuliang
Carlson, Jennifer
Friedman, Lori
Dey, Nandini
Leyland-Jones, Brian
CANCER RESEARCH, 2015, 75
[23] SORAFENIB ALTERS BIOLOGICAL BEHAVIORS OF ANOIKIS-RESISTANT RENAL CANCER CELLS THROUGH INHIBITION OF PI3K-AKT AND RAF-MEK-ERK SIGNALING
Yifei, X.
Zengshu, X.
Xuechao, L.
Wenzhen, A.
Dehong, C.
Yajun, X.
INTERNATIONAL JOURNAL OF UROLOGY, 2012, 19 : 377 - 377
[24] Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways
Carlos García-Echeverría
Purinergic Signalling, 2009, 5 : 117 - 125
[25] Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways
Garcia-Echeverria, Carlos
PURINERGIC SIGNALLING, 2009, 5 (01) : 117 - 125
[26] PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Antonino Glaviano
Aaron S. C. Foo
Hiu Y. Lam
Kenneth C. H. Yap
William Jacot
Robert H. Jones
Huiyan Eng
Madhumathy G. Nair
Pooyan Makvandi
Birgit Geoerger
Matthew H. Kulke
Richard D. Baird
Jyothi S. Prabhu
Daniela Carbone
Camilla Pecoraro
Daniel B. L. Teh
Gautam Sethi
Vincenzo Cavalieri
Kevin H. Lin
Nathalie R. Javidi-Sharifi
Eneda Toska
Matthew S. Davids
Jennifer R. Brown
Patrizia Diana
Justin Stebbing
David A. Fruman
Alan P. Kumar
Molecular Cancer, 22
[27] PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, Antonino
Foo, Aaron S. C.
Lam, Hiu Y.
Yap, Kenneth C. H.
Jacot, William
Jones, Robert H.
Eng, Huiyan
Nair, Madhumathy G.
Makvandi, Pooyan
Geoerger, Birgit
Kulke, Matthew H.
Baird, Richard D.
Prabhu, Jyothi S.
Carbone, Daniela
Pecoraro, Camilla
Teh, Daniel B. L.
Sethi, Gautam
Cavalieri, Vincenzo
Lin, Kevin H.
Javidi-Sharifi, Nathalie R.
Toska, Eneda
Davids, Matthew S.
Brown, Jennifer R.
Diana, Patrizia
Stebbing, Justin
Fruman, David A.
Kumar, Alan P.
MOLECULAR CANCER, 2023, 22 (01)
[28] PI3K/Akt/mTOR and Raf/MEK/ERK signaling pathways perturbations in non-functioning pituitary adenomas
Hadara Rubinfeld
Ilan Shimon
Endocrine, 2012, 42 : 285 - 291
[29] Therapeutic Resistance Resulting From Mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Signaling Pathways
McCubrey, James A.
Steelman, Linda S.
Kempf, C. Ruth
Chappell, William H.
Abrams, Stephen L.
Stivala, Franca
Malaponte, Graziella
Nicoletti, Ferdinando
Libra, Massimo
Baesecke, Joerg
Maksimovic-Ivanic, Danijela
Mijatovic, Sanja
Montalto, Giuseppe
Cervello, Melchiorre
Cocco, Lucio
Martelli, Alberto M.
JOURNAL OF CELLULAR PHYSIOLOGY, 2011, 226 (11) : 2762 - 2781
[30] PI3K/Akt/mTOR and Raf/MEK/ERK signaling pathways perturbations in non-functioning pituitary adenomas
Rubinfeld, Hadara
Shimon, Ilan
ENDOCRINE, 2012, 42 (02) : 285 - 291

← 1 2 3 4 5 →